Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Charles River Laboratories Intl (NY: CRL ) 212.44 UNCHANGED Streaming Delayed Price Updated: 7:00 PM EDT, Jun 13, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Charles River Laboratories Intl < Previous 1 2 3 4 5 Next > Charles River Acquires Viral Vector Player For $350M May 17, 2021 Contract researcher Charles River Laboratories International Inc (NYSE: CRL) will dole out $292.5 million for gene therapy CDMO Vigene Biosciences with the... Via Benzinga Charles River Labs Joins Elite List Of Stocks With 95-Plus Composite Rating May 05, 2021 Charles River Labs' Accumulation/Distribution Rating of A, on an A+ to E scale, shows heavy buying by institutional investors over the last 13 weeks. Via Investor's Business Daily Charles River Laboratories International Inc (CRL) Q1 2021 Earnings Call Transcript May 04, 2021 CRL earnings call for the period ending March 31, 2021. Via The Motley Fool Topics Earnings Exposures Financial Charles River: Q1 Earnings Insights May 04, 2021 Shares of Charles River (NYSE:CRL) decreased 0.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 37.50% year over... Via Benzinga Three Medical Stocks To Watch, Including One With A Potential Breakout April 22, 2021 Two have recent breakouts under their belts while a third is eyeing a fresh buy point. Via Investor's Business Daily Stocks That Hit 52-Week Highs On Thursday April 15, 2021 Thursday morning saw 166 companies set new 52-week highs. Interesting Highlights: The largest company by market cap to hit a new 52-week high was Microsoft (NASDAQ:... Via Benzinga Medpace Holdings Stock At The Top Of Buy Range With Earnings On Deck April 20, 2021 Medpace is in a potential buy range with its next earnings report scheduled for Apr. 26. The medical stock is about 3% above a 177.22 buy point from a second-stage... Read More Via Investor's Business Daily < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.